Oral Toxicity of 1,2-Dithiole-3-Thione,a Potential Cancer Chemopreventive Agent,in the Rat

Abstract

This study examined the toxicity of 1,2-dithiole-3-thione (D3T) in rats following 14 days of daily oral (gavage) administration. D3T, an extensive inducer of hepatic phase II drug-metabolizing enzymes, has demonstrated cancer preventive efficacy in rodent models of tumorigenesis and is a candidate drug for cancer prevention. Male and female CD rats (5/sex/dose group) received D3T at dose levels of 0 (corn oil vehicle control), 2, 6, 20, and 60 mg/kg/day. Oral administration of D3T for 14 days at 20 mg/kg/day resulted in decreased activity, lethargy, rough coat, and piloerection, and toxicologically significant lesions in the stomach, characterized by apoptotic necrosis and hyperplasia of the glandular mucosa. Administration of D3T at 60 mg/kg/day produced anemia in females, decreased body weight gain in males, and increased vacuolation of adrenal cortical cells. Increased liver weights, vacuolation of hepatocytes, and serum chemistry changes, indicative of altered liver function, were observed at 6 mg/kg/day, which were likely due to a pharmacologic effect of D3T on the liver and not considered to be toxicologically significant. Under the conditions of the study, the no-observed-adverse effect level (NOAEL) was 6 mg/kg/day.

Keywords

Anemia Cancer Chemoprevention Chemopreventive Agent Dithiolethione Gastric Toxicity Liver

References

Benson, A. B. 1993. Oltipraz: A laboratory and clinical review. J. Cell. Biochem. Suppl. 17F:278–291.

Crowell, J. A. , J. G. Page , L. E. Rodman , J. E. Heath , E. I. Goldenthal , L. B. Hall , and G. J. Kelloff . 1997. Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent. Fundam. Appl. Toxicol. 35:9–21.

Goel, V . 1998. Tamoxifen and breast cancer prevention: What should you tell your patients? Can. Med. Assoc. J. 158:1615–1617.

Groopman, J. D. , P. DeMatos , P. A. Egner , A. Love-Hunt , and T. W. Kensler . 1992. Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprevention by 1,2-dithiole-3-thione in rats. Carcinogenesis 13:101–106.

Hall, P. M. 1994. Histopathology of drug-induced liver disease. In Drug-induced liver disease, ed. G.C. Farrell , 115–151. New York: Churchill-Livingstone.

Hong, K. H. , and M. B. Sporn . 1997. Recent advances in chemoprevention of cancer. Science 278:1073–1077.

Kelloff, G. J. , C. W. Boone , J. A. Crowell , V. E. Steele , R. Lubet , and C. C. Sigman . 1994a. Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol. Biomarkers Prev. 3:85–98.

Kelloff, G. J. , C. W. Boone , V. E. Steele , J. R. Fay , R. A. Lubet , J. A. Crowell , and C. C. Sigman . 1994b. Mechanistic considerations in chemopreventive drug development. J. Cell. Biochem. Suppl. 20:1–24.

Kensler, T. W. 1997. Chemoprevention by inducers of carcinogen detoxification enzymes. Environ. Health Persp. 105(Suppl. 4):965–970.

10.

Kensler, T. W. , P. A. Egner , P. M. Dolan , J. D. Groopman , and B. D. Roebuck . 1987. Mechanism of protection against aflatoxin tumorgenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) and related 1,2-dithio-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 47:4271–4277.

11.

Kensler, T. W. , J. D. Groopman , D. L. Eaton , T. J. Curphey , and B. D. Roebuck . 1992. Potent inhibition of aflatoxin-induced hepatic tumorgenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione. Carcinogenesis 13:95–100.

12.

Kensler, T. W. , X. He , M. Otieno , P. A. Egner , L. P. Jacobson , B. Chen , J. S. Wang , Y. R. Zhu , B. C. Zhang , J. B. Wang , Y. Wu , Q. N. Zhang , G. S. Qian , S. Y. Kuang , X. Fang , Y. F. Li , L. Y. Yu , H. J. Prochaska , N. E. Davidson , G. B. Gordon , M. B. Gorman , A. Zarba , C. Enger , A. Munoz , K. J. Helzlsouer , and J. D. Groopman . 1998. Oltipraz chemoprevention trial in Qidong, People's Republic of China: Modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 7:127–134.

13.

Levin, S. , T. J. Bucci , S. M. Cohen , A. S. Fix , J. F. Hardisty , E. K. LeGrand , R. F. Maronpot , and B. F. Trump . 1999. The nomenclature of cell death: Recommendations of an ad hoc committee of the Society of Toxicologic Pathologists. Toxicol. Pathol. 27:484–490.

14.

Maxuitenko, Y. Y. , A. H. Libby , H. H. Joyner , T. J. Curphy , D. L. MacMillan , T. W. Kensler , and B. D. Roebuck . 1998. Identification of dithiolethiones with better chemopreventive properties than Oltipraz. Carcinogenesis 19:1609–1615.

15.

Meyer, D. J. , J. M. Harris , K. S. Gilmore , B. Coles , T. W. Kensler , and B. Ketterer . 1993. Quantitation of tissue-and sex-specific induction of rat GSH transferase subunits by dietary 1,2-dithiole-3-thiones. Carcinogenesis 14:567–572.

16.

Primiano, T. , T. W. Kensler , P. Kuppusamy , J. L. Zweier , and T. R. Sutter . 1996. Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones. Carcinogenesis 17:2291–2296.

17.

Sagartz, J. E. , S. W. Curtiss , R. T. Bunch , J. C. Davila , D. L. Morris , and C. L. Alden . 1998. Phenobarbital does not promote hepatic tumorigenesis in a twenty-six-week bioassay in p53 heterozygous mice. Toxicol. Pathol. 26:492–500.

18.

Smigel, K . 1998. Breast cancer prevention trial shows major benefit, some risk. J. Natl. Cancer Inst. 90:647–648.

19.

Vos, R. M. E. , and P. J. Van Bladeren . 1990. Glutathione S-transferases in relation to their role in biotransformation of xenobiotics. Chem. Biol. Interact. 75:241–265.

20.

York, M. J. , and G. O. Evans . 1996. Electrolyte and fluid balance. In Animal clinical chemistry, ed. G. O. Evans , 170–171. Bristol, PA: Taylor and Francis.